UK Marketing Authorisation for Chikungunya Vaccine IXCHIQ Revoked Following Benefit–Risk Review – Valneva
Valneva SE announced that, following a further benefit-risk assessment of Ixchiq for travelers by the United Kingdom’s (UK) Commission on Human Medicines (CHM), the UK marketing authorization for… read more.
